{"id":"autologous-tolerogenic-dendritic-cells","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Autologous Tolerogenic Dendritic cells work by inducing tolerogenic dendritic cells, which play a crucial role in suppressing immune responses and promoting tolerance to self-antigens.","oneSentence":"Induction of tolerogenic dendritic cells to suppress immune responses","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:39:02.096Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune diseases"}]},"trialDetails":[{"nctId":"NCT04530318","phase":"PHASE2","title":"Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Judit Pich","startDate":"2020-01-27","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":45},{"nctId":"NCT04590872","phase":"PHASE1","title":"An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-06-16","conditions":"Type 1 Diabetes Mellitus","enrollment":6},{"nctId":"NCT07020715","phase":"PHASE2","title":"A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2026-03-01","conditions":"Multiple Sclerosis","enrollment":14},{"nctId":"NCT07163403","phase":"PHASE1","title":"First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2025-09-04","conditions":"Lynch Syndrome","enrollment":20},{"nctId":"NCT05207995","phase":"PHASE1, PHASE2","title":"The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells","status":"COMPLETED","sponsor":"Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus","startDate":"2022-03-01","conditions":"Diabetes Mellitus","enrollment":32},{"nctId":"NCT06852625","phase":"PHASE1","title":"Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients","status":"NOT_YET_RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2025-05","conditions":"Kidney Transplant Rejection","enrollment":30},{"nctId":"NCT01352858","phase":"PHASE1","title":"Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis (AutoDECRA)","status":"COMPLETED","sponsor":"Newcastle University","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":14},{"nctId":"NCT02903537","phase":"PHASE1","title":"Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)","status":"UNKNOWN","sponsor":"Fundació Institut Germans Trias i Pujol","startDate":"2017-07-06","conditions":"Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive","enrollment":16},{"nctId":"NCT05554484","phase":"PHASE1, PHASE2","title":"AMI-DC in Patients With Anterior Wall Myocardial Infarction","status":"UNKNOWN","sponsor":"The Catholic University of Korea","startDate":"2021-06-07","conditions":"Myocardial Infarction","enrollment":30},{"nctId":"NCT05251870","phase":"PHASE1, PHASE2","title":"Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2021-08-17","conditions":"Rheumatoid Arthritis","enrollment":18},{"nctId":"NCT03337165","phase":"PHASE1","title":"Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Russian Academy of Medical Sciences","startDate":"2016-12","conditions":"Musculoskeletal Diseases, Joint Disease, Arthritis","enrollment":10},{"nctId":"NCT02252055","phase":"PHASE1, PHASE2","title":"The ONE Study ATDC Trial","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2015-03-19","conditions":"Renal Failure, End Stage","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Autologous Tolerogenic Dendritic cells","genericName":"Autologous Tolerogenic Dendritic cells","companyName":"Fundacion Clinic per a la Recerca Biomédica","companyId":"fundacion-clinic-per-a-la-recerca-biom-dica","modality":"Biologic","firstApprovalDate":"","aiSummary":"Induction of tolerogenic dendritic cells to suppress immune responses Used for Autoimmune diseases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}